{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Motesanib_Diphosphate",
  "nciThesaurus": {
    "casRegistry": "857876-30-3",
    "chebiId": "",
    "chemicalFormula": "C22H23N5O.2H3O4P",
    "definition": "The orally bioavailable diphosphate salt of a multiple-receptor tyrosine kinase inhibitor with potential antineoplastic activity. Motesanib selectively targets and inhibits vascular endothelial growth factor (VEGFR), platelet-derived growth factor (PDGFR), kit, and Ret receptors, thereby inhibiting angiogenesis and cellular proliferation.",
    "fdaUniiCode": "T6Q3060U91",
    "identifier": "C48374",
    "preferredName": "Motesanib Diphosphate",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C1967"
    ],
    "synonyms": [
      "3-Pyridinecarboxamide, N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-((4-pyridinylmethyl)amino)-, phosphate (1:2)",
      "AMG 706",
      "MOTESANIB DIPHOSPHATE",
      "Motesanib Diphosphate"
    ]
  }
}